🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT07791914
Starting soon Phase 4

Oral Switch in Pediatric Bloodstream Infections

NCT07791914 · tracked via the Priya Life Science Denmark tracker
Sponsor
Ulrikka Nygaard
Phase
Phase 4
Started
2026-09-01
Last updated
2026-08-28

Condition(s) studied

Bloodstream InfectionBacteremia Sepsis

Investigational drug(s) / intervention(s)

Oral antibiotic therapyStandard IV antibiotic therapy

Oral antibiotic therapy: Participants randomised to the experimental arm will switch to oral antibiotic therapy as soon as possible after clinical stability and within 4 days after initiation of effective IV antibiotic therapy. Children who have not received antibiotics, or who have received oral antibiotics before the blood culture becomes positive, may also be randomised; thus, prior IV therapy is not required in the experimental arm.

Standard IV antibiotic therapy: Participants allocated to the control group will continue IV therapy for at least 5 days after initiation of effective IV antibiotic therapy, with 7 days recommended, followed by oral step-down if appropriate.

Study summary

This nationwide, multicenter, randomized, non-inferiority trial of children and adolescents with uncomplicated bloodstream infections aims to investigate if early-oral antibiotic switch (experimental arm) is non-inferior to standard intravenous antibiotics (control arm) with respect to treatment failure.

Eligibility

Sex
ALL
Min age
4 Weeks
Max age
17 Years
Healthy volunteers
No
INCLUSION CRITERIA 1. Age 4 weeks to 17 years 2. Positive blood culture with a i) pathogenic bacterium (eg, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacterales, Fusobacterium spp. and other pathogenic bacteria) or ii) preliminary blood culture result (eg, Gram-negative rods or Gram-positive cocci in clusters/chains) judged by the investigator to be clinically relevant (ie, not a contaminant) and for which IV antibiotic therapy would be indicated according to standard guidelines 3. Clinical stability, defined as: (a) respiratory and haemodynamic stability, without need for oxygen, IV fluid therapy or inotropic support; and (b) well-appearing with signs of clinical improvement (eg, improved physical activity), as judged by the investigator 4. Tolerating oral fluids and diet, as judged by the investigator 5. Within the randomization window (see below) 6. Informed consent obtained from a parent or guardian, and from the patient if aged 15 years or older Randomization window: Randomization will take place (1) as soon as possible after eligibility is confirmed, and (2) before completion of a maximum of 4 days (96 hours) of effective IV antibiotic therapy, including the duration of the last IV dose (eg, 8 hours for penicillin and 24 hours for ceftriaxone) EXCLUSION CRITERIA 1. Complicated infections: a. Suspicion of endocarditis (echocardiography not performed routinely), b. Suspicion of CNS infection or post-septal cellulitis, c. Foreign material (eg, bone infection involving prosthetic material). d. Complicated postoperative course (eg, perforated appendicitis) 2. Blood culture positive with a. Neisseria meningitidis, b. Streptococcus pneumoniae if afebrile within 24 hours of blood culture collection, c. bacteria considered possible contaminants (eg, coagulase-negative staphylococci, Corynebacterium spp., Micrococcus spp.) 3. Premature infants with a corrected age of less than 28 days 4. No available suitable oral antibiotic (eg, due to antimicrobial resistance or contraindications) 5. Known chronic disease associated with an increased risk of severe infection: i) Immunosuppression, e.g., chemotherapy or biological therapy predisposing to severe infections, ii) Permanent central venous catheter due to an underlying condition, iii) Severe urinary tract abnormalities predisposing to bacteremia, including children receiving prophylactic antibiotic treatment.

Primary outcome measure(s)

Trial sites (18)

FacilityCityRegionStatus
Department of Pediatrics, Aabenraa Hospital Aabenraa Denmark
Department of Pediatrics, Aalborg University Hospital Aalborg Denmark
Aarhus University Hospital Aarhus Denmark
Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark
Department of Pediatrics, Esbjerg Hospital Esbjerg Denmark
Department of Paediatrics and adolescent medicine, NIDO Danmark, Gødstrup Hospital Gødstrup Denmark
Department of Pediatrics, Herlev Hospital Herlev Denmark
Department of Pediatrics, Hillerød Hospital Hillerød Denmark
Department of Pediatrics, Hjørring Hospital Hjørring Denmark
Department of Pediatrics, Holbæk Hospital Holbæk Denmark
Department of Pediatrics, Hvidovre Hospital Hvidovre Denmark
Department of Pediatrics, Kolding Hospital Kolding Denmark
Department of Pediatrics, Nykøbing Falster Hospital Nykøbing Falster Denmark
Hans Christian Andersen Children's Hospital, Odense University Hospital Odense Denmark
Department of Pediatrics, Randers Hospital Randers Denmark
Department of Pediatrics, Roskilde University Hospital Roskilde Denmark
Department of Pediatrics, Slagelse Hospital Slagelse Denmark
Department of Pediatrics, Viborg Hospital Viborg Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07791914 on ClinicalTrials.gov ↗ ← All trials in Denmark